Updates and Events
KZR-616 Shows Promise According to Results Reported at EULAR

Kezar Life Sciences announced positive results from the MISSION Phase 1 study testing the investigational KZR-616 as a treatment for lupus.  The presentation was at the European League Against Rheumatism (EULAR) 2019 annual meeting. The primary goal of the study was to assess if KZR-616 is safe and well tolerated. The study also looked at […] READ MORE

Stelara® Effective Over One Year and Reduces Severe Flares

Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over one year. Both highlight the benefit of ustekinumab on disease activity and the rate of severe flares. Ustekinumab reduced the rate of severe flares four times as much as placebo by week 24. The rate of […] READ MORE

Rituximab Effective for Maintenance Lupus Treatment Shows Study

June 13, 2019 A study published in Arthritis & Rheumatology found that rituximab was helpful as a maintenance therapy for tough-to-treat lupus patients. Maintenance treatment refers to one designed to help a main treatment work.  Rituximab is approved by the U.S. Food and Drug Administration for two types of cancer. It is sold by the […] READ MORE

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial sponsored by the Lupus Research Alliance and conducted through its Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  Entitled VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE), the study showed that a […] READ MORE

Results Presented at EULAR Find Investigational Lupus Treatment NKTR-358 Safe

June 13, 2019 New results from a clinical study with healthy volunteers found the investigational compound NKTR-358 safe and well-tolerated, providing support for testing it as a treatment for autoimmune diseases such as lupus. Researchers have known that impaired production of interleukin-2 (IL-2) and dysfunctioning regulatory T cells called Tregs are key to breaking down […] READ MORE

Making Good Immune System Cells Turn Bad

Normally helpful immune system cells become harmful in patients with lupus. With a Novel Research Grant from the LRA, a team led by Dr. Frances Lund of the University of Alabama at Birmingham and Dr. Ignacio Sanz of Emory University in Atlanta and has discovered one possible reason why. The immune cells known as B […] READ MORE

Lupus Counts as a National Men’s Health Issue

June is National Men’s Health Month, when the Lupus Research Alliance works to raise awareness of lupus as a health issue among men to help early diagnosis and treatment.  If a man has symptoms like extreme fatigue, skin rashes, joint pain and unexplained fevers – symptoms that can indicate lupus – he should talk to […] READ MORE

Anti-Nuclear Antibodies May Confuse Lupus Diagnosis

Patients who may have lupus typically undergo an “ANA” test to detect anti-nuclear antibodies (ANAs). Lupus Research Alliance Distinguished Innovator Award recipient Dr. Shu Man Fu of the University of Virginia and colleagues found that people who don’t have lupus also produce ANAs. This suggests that patients can not be diagnosed with lupus just because […] READ MORE

Join Us at Lupus Research and Advocacy Conference

Find Out How Lupus Research Can Transform Lives at a Free Conference and Cocktail Reception  Learn about the newest advances in lupus research and how to advocate for more research funding from the federal government, to support future discoveries. Wednesday, July 17, 2019 5:45 PM Reception 7:00 PM Panel Discussion iHeartMedia 125 W 55th Street […] READ MORE

New Study Partly Funded by LRA Reveals Novel Lupus Drug Targets

NEW YORK, NY – May 29. Researchers partly funded by the Lupus Research Alliance (LRA) have found possible new targets for drugs to treat lupus after snapping the first close-up of a molecule that promotes inflammation. The molecule that Target Identification in Lupus (TIL) grant recipient Dr. Roger Greenberg at University of Pennsylvania and Dr. […] READ MORE

Discovering Lupus Heterogeneity

May 22, 2019 Lupus is heterogeneous, meaning that symptoms are many and vary widely from patient to patient — one person may develop a rash, while another may have high blood pressure, joint pain, and anemia. About two thirds of adults with lupus have above-normal levels of immune system molecules called type I interferons that […] READ MORE

Learn and connect with our community!